Skip to main content
. 2023 Feb 16;24(4):3972. doi: 10.3390/ijms24043972

Figure 2.

Figure 2

The protease inhibitors block SARS-CoV-2 replication in human PCLS of two different donors. (A) Scheme of the experimental setup. (B,C) Human PCLS were incubated with 30 µM of selected protease inhibitors and infected with SARS-CoV-2. All infections were performed in triplicates. Viral infectivity was determined by infecting Vero cells in duplicates with the supernatants. Viral loads were determined by RT-qPCR.